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Aim of the study was to evaluate (1) the overall use of bone graft substitutes, auto-
grafts and allografts, (2) of different types of bone graft substitutes (calcium sulfate,
calcium phosphate, calcium phosphate ceramics or polymethyl methacrylate) and of
different bone grafts (cancellous vs. cortical), and (3) the use of antibiotic-loading of
bone graft substitutes in orthopedic surgery in Germany. Gross data were provided
from the Federal Statistical Office of Germany and revealed an overall increase in
bone defect reconstruction procedures using bone graft substitutes, autografts and
allografts from 86,294 in 2008 to 99,863 cases in 2018 (+15.7%). The relative use of
bone graft substitutes for these interventions strongly increased from 11.8% in 2008
(10,163 cases) to 23.9% in 2018 (23,838 cases) with an increase of +134.4%. Fur-
thermore, antibiotic-loaded bone graft substitutes were implanted more frequently
with an overall increase of +194% (2008: n = 2,657; 2018: n = 7,811). The work
shows an increasing use of bone graft substitutes and antibiotic-loaded bone graft
substitutes over the last 10 years in Germany.
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1 | INTRODUCTION
In orthopedic and trauma surgery, bone defects pose an increasing
clinical problem in daily practice. These result from bone infections
and tumors, which in most cases require surgical resection followed
by bony reconstruction. In addition, fractures after high-energy
trauma and osteoporotic fractures are frequently accompanied by
bone defects necessitating bone augmentation procedures.1 Osteopo-
rotic fractures are the expected main driver for an increased number
of bone defects. Numbers of individuals at high risk of osteoporotic
fractures are estimated to double until 2040 in the Western World
due to demographic aging.2 Even today, half a million patients are
reported to receive bone defect repairs per annum in the United
States and Europe with an estimated cost exceeding US$ 3 billion.3
Bone defect reconstruction can be achieved by the use of
autografts, allografts and, biomaterial-based bone graft substitutes
containing ceramics, synthetic or natural polymers.4,5 Hitherto,
autogenous bone grafting has been considered the gold standard.
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Autograft not only provides osteogenic but also osteoconductive and
osteoinductive properties. However, drawbacks associated with the
use of autologous bone grafts are limited availability, donor site mor-
bidity and increased operation time. From the clinical perspective
those shortcomings were the key drivers for advances in biomedical
research to develop bone graft substitutes for bone defect recon-
struction in the past.6 Efforts in bone tissue engineering are based on
the benchmark autograft: providing a biocompatible scaffold similar to
natural bone, osteogenesis by cells in the osteoconductive scaffold,
growth factors directing and promoting cell growth as well as devel-
opment to improve bone ingrowth and remodeling, and finally, suffi-
cient vascularization for nutrient supply and clearance needs.7
Impaired vascularization entails an increased risk of foreign body
infection. Application of local antibiotics evolved as one of the central
tenets for prevention and treatment of bone infections. Thus, addi-
tional application of antibiotics in combination with allografts and syn-
thetic bone graft, which are otherwise prone to bacterial infections,
has been implied in recent years.8,9 Despite efforts in basic research
with progressively implementation of bone graft substitutes in the
orthopedic biomaterial markets, no data are available, which demon-
strate recent trends in use of bone graft substitutes and autologous as
well as allogenic bone for bone defect reconstruction.
We therefore asked: What are the general trends for use of bone
graft substitutes and bone grafts in the recent decade? What trends
have been developed in use of different bone graft substitutes and
bone grafts? Is there an increase in bone graft substitute use with
additional antibiotics for local anti-infective treatment?
2 | MATERIALS AND METHODS
2.1 | Data source
Data were provided by the German Federal Statistical Office
(Destatis). For our analysis, historical data from 2008 through 2018
were utilized. Since 2004 all somatic departments have to classify
their cases according to the diagnosis related groups (DRG). Lump-
sum payment is based on DRGs which are generated by diagnosis
codes as well as surgery and procedure keys (Operation and Proce-
dure Classification System [OPS] codes). Thus, procedure numbers for
use of bone substitutes and bone grafts were available from all Ger-
man hospitals for inpatient procedures within the analyzed period. All
kinds of clinical applications including off-label use of bone graft sub-
stitutes were included in our analysis.
2.2 | Data processing
Surgery and procedure keys (OPS codes) were used to identify all pro-
cedures being performed using bone substitutes or bone grafts. We
focused on OPS codes for usage of bone grafts and their substitutes
treating bone defects at the extremities and pelvis, which are summa-
rized under the OPS codes 5–785 and 5–784. These include all types
of bone grafting and transplantation (5–784), but also exclude the clo-
sure or filling of iatrogenically created or access-related bone defects
with local tissue.
F IGURE 1 Total use of biomaterials, autologous and allogenic bone grafts in orthopedic surgery in Germany from 2008 to 2018. Total
numbers increase over time peaking in 2017. The distribution of used biomaterials, autologous or allogenic bone grafts remain roughly the same
over the 11-year period
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The implantation of bone substitutes (5–785) excludes all
interventions for endoprosthetic joint and bone replacement. For
bone substitutes, the OPS codes were used to distinguish between
bone cements without (5–785.0) and with added antibiotics
(5–785.1). For ceramics a distinction was made between ceramics
with additional antibiotics (5–785.5) and those without (5–785.2 and
5–785.3). Other codes such as metallic bone graft substitutes
(5–785.4) and other alloplastic bone graft substitutes without
(5–785.6) and with (5–785.7) antibiotics were also included in the
analysis. Autologous bone transplantation was discriminated as
follows: autologous cancellous bone (5–784.0, 5–784.c), autologous
cortical bone graft (5–784.1, 5–784.2, 5–784.d), other autologous
bone grafts (5–784.3, 5–784.4, 5–784. 5, 5–784.a); allogenic
procedures: allogenic cancellous bone (5–784.7, 5–784.9, 5–784.e),
allogenic cortical bone grafts (5–784.8, 5–784.f), demineralized bone
matrix (5–784.b), allogenic bone grafts (5–784.6).
2.3 | Data analysis
Data was analyzed and graphically displayed using the statistical
software SPSS Version 26.0 (IBM, SPSS Inc. Armonk, New York).
3 | RESULTS
3.1 | Overview of 1,090,167 cases—high increase
in the use of bone graft substitutes
This works relies on the analysis of a total of 1,090,167 procedures in
orthopedic surgery in Germany from 2008 through 2018.
From 2008 through 2018, an increased number of interven-
tions in orthopedic surgery using bone graft substitutes and bone
grafts were recorded. While a total of 86,294 procedures were
TABLE 1 Comparison of absolute and relative numbers of bone graft and biomaterial procedures between 2008 and 2018
2008 2018 Percentage changes from
2008 through 2018
Absolute numbers Percentage share Absolute numbers Percentage share
Total procedures 86,294 100% 99,863 100% +15.7%
Autologous bone graft 63,929 74.1% 54,784 54.9% 14.3%
Allogenic bone graft 12,202 14.1% 21,241 21.3% +74.1%
Biomaterials 10,163 11.8% 23,838 23.9% +134.4%
F IGURE 2 Illustration of the application of biomaterials for bone defect reconstruction. Bone cements were used slightly more frequently
than ceramics for bone defect reconstruction in extremities and pelvis
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performed in 2008, 99,863 procedures were carried out in 2018
(+15.7%) (Figure 1). The largest number of bone defect recon-
struction procedures was identified in 2017 (106,953 procedures).
The percentage of bone graft substitutes increased over the years.
While bone graft substitutes accounted for 11.8% of all bone
replacement procedures in 2008 (10,163 procedures), this number
has risen to 23.8% in 2018 (23,838 procedures). This represents
an increase of 134.4% (Table 1).
3.2 | Analysis of the use of bone graft
substitutes—growing use of all type of materials,
particularly for ceramics
The increasing use of bone graft substitutes results from a growth
of absolute numbers of all analyzed subgroups such as bone
cements, ceramics, and other biomaterials. Similar to the increase
in the total amount of bone graft substitute applications, an
increase in clinical use was observed for bone cements (2008:
3,884 procedures; 2018: 8,843 procedures, +127.7%) and
ceramics (2008: 5,202 procedures; 2018: 9,981 procedures,
+91.9%) (Figure 2). The bone substitutes included under “other
biomaterials” such as metallic replacement materials or bioactive
glass have also been increasingly used over the years. While 1,077
procedures were coded in 2008, a total of 5,014 coded proce-
dures with “other biomaterials” for defect reconstruction of
extremities and pelvis were registered in 2018 (+365.8%).
Looking at the percentage weighting of the individual years, it is
remarkable that the specific use of ceramics accounted for 51.2%
of all bone graft substitutes in 2008, decreasing to 41.9% of all
bone graft substitutes in 2018. In contrast, the proportion of bone
cements remained constant (2008: 38.2% vs. 2018: 37.1%). Other
biomaterials were used much more frequently over the observed
11-year period (2008: 10.6% vs. 2018: 21%) (Table 2).
TABLE 2 Comparison of biomaterial applications in extremities and pelvis between 2008 and 2018
2008 2018 Percentage changes from
2008 through 2018
Absolute numbers Percentage share Absolute numbers Percentage share
Total numbers 10,163 100% 23,838 100% +134.4%
Ceramics 5,202 51.2% 9,981 41.9% +91.9%
Bone cements 3,884 38.2% 8,843 37.1% +127.7%
Others 1,077 10.6% 5,014 21.0% +365.6%
F IGURE 3 Total numbers of biomaterial application with and without additional local antibiotics. The share of supplemental antibiotics in
biomaterials increases from 2008 through 2018
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3.3 | Antibiotic-loaded bone graft substitutes—
increasing use
Regarding the use of bone graft substitutes containing antibiotics, an
increase in absolute numbers and an increased relative use can be observed
over the investigation period. In 2008, there were 2,657 procedures, for
which the use of bone graft substitutes with added antibiotics was coded.
In 2018, there were 7,811 procedures (+194%). The proportion of bone
graft substitutes with added antibiotics increased over the observational
period (2008: 2,657 cases, 25%; 2018: 7,811 cases, 32.8%) (Figure 3).
F IGURE 4 Overview of clinical application of autologous bone grafts from 2008 through 2018. Total numbers decrease over time.
Percentage share of cancellous or cortical grafts as well as other autologous transplant procedures remains roughly the same over the 11-year
period
F IGURE 5 Illustration of absolute numbers of allogenic bone transplantations from 2008 through 2018 in Germany. Total numbers increase
over time
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3.4 | Autograft and allograft procedures—
decreasing autograft and increasing allograft
procedures
The proportion of allografts has also increased in absolute and relative
terms over the years. Between 2008 and 2018 the number of
transplanted allografts in Germany rose from 12,202 to 21,241
(+74.1%). At the same time, the number of autologous bone trans-
plants has decreased slightly over the 11-year period. From 63,929
procedures with autologous bone transplantation in 2008, 54,784
interventions could still be identified in 2018 (14.3%). The propor-
tion of autologous bone grafts has also decreased over time. Autolo-
gous bone transplants accounted for 74.1% of all bone defect
reconstructions in the extremities and pelvis in 2008, whereas auto-
grafts were still used in 55% of all bone defect reconstructions
in 2018.
Looking at autologous and allogeneic bone transplantation, can-
cellous bone grafting is by far the most common procedure over the
years for both different types of bone grafting. Autologous cancellous
bone grafting was performed 50,104 times in 2008 (78.4%). In 2018,
there were still 41,988 autologous cancellous bone-grafting proce-
dures (76.6%) (Figure 4). The situation is similar for allogeneic bone
transplantation. Cancellous bone grafting accounted for the majority
of procedures in allogenic bone grafting in all years (2008: 83.7%,
10,212 procedures; 2018: 79.0%, 16,774 procedures) (Figure 5).
Although rarely used, a considerable increase in the application of
demineralized bone matrix can be observed from 2009 to 2018.
Whereas 288 procedures using demineralized bone matrix were regis-
tered in 2009, the number has increased continuously over the
observed period. In 2018, 1,355 procedures with demineralized bone
matrix were coded. This corresponds to a proportion of allografts of
6.4% in 2018.
4 | DISCUSSION
Between 2008 and 2018, the total number of procedures involving
the use of bone graft substitutes, autografts, and allografts for bone
defect reconstruction in extremities and pelvis increased (2008:
86,294 procedures; 2018: 99,863 procedures, +15.7%). Interestingly,
the prevalence of bone graft substitutes and allograft application
increased over the 11-year period, while autografts showed a
decrease in absolute numbers (2008: n = 63,929, 2018: n = 54,784,
14.3%). This reflects a considerable decrease in percentage for
autologous bone grafts (2008: 74.1%; 2018: 55%). An increase of allo-
graft usage of 74.1% (2008: n = 12,202; 2018: n = 21,241) and an
even larger increase of bone substitute applications of 134.4% (2008:
n = 10,163; 2018: n = 23,838) has been demonstrated. As far as
these data can be compared to the only available study dealing with
numbers of bone graft and bone substitutes in the United States, our
findings contradict those results reporting a decrease in bone graft
use and even a slighter decrease in application of bone graft substi-
tutes.10 Although Kinaci and co-workers examined the trends from
1992 to 2007 in the US and described a proportion of bone substitute
procedures of 17%, which is similar to our data, the different exam-
ined time period and countries as well as inclusion of additional spine
procedures limit the comparability of both studies.10 Market analyses
predict a global compound annual growth rate of 5.2% and a total
market of 4.4 billion US-Dollars for bone grafts and bone substitutes
in 2027. Those projections are similar to the observed overall increase
in bone defect reconstruction procedures reported in our study.11
Our data demonstrate different trends for use of autografts, allo-
genic bone and bone substitutes. The decreased use of autografts and
increased use of allografts and bone graft substitutes suggests that
risks and benefits are weighed differently in clinical routine over time.
Reasons for this development are manifold. Harvesting of autologous
bone graft entails different downsides. Beside longer operation time
those are subsumed under the term donor site morbidity, which
includes persistent pelvic pain, postoperative hematoma, nerve injury
or fracture of the pelvic bone. Those complications are reported to be
up to 20%. Alternatives to iliac crest bone graft harvesting such as the
reamer irrigator aspirator (RIA) technique also poses a risk for donor
site morbidity of about 6% in the long bones.6 Despite this less risky
harvesting alternative, other choices for bone grafting are made by
the treating surgeons. A decrease of drawbacks for allograft use such
as a minimal infection risk for hepatitis and HIV nowadays, confers
allografts a better acceptance among patients and users.12 In addition,
downsides reported after allograft use such as sensitization of the
immune system seem not to be considered negative for bone defect
reconstruction.13 Furthermore, promoted use of bone graft substi-
tutes by the industry might account for the changes observed in the
study. Besides, treating surgeons could have recognized improve-
ments being made in developing better biomaterials for bone graft
substitutes in the last decade.14 Thus, bone substitutes could have
found their way in clinical practice more and more. Monetary reasons
for use of bone graft substitutes and an increased DRG reimburse-
ment rate by coding bone graft substitutes could be another cause for
further increase of bone substitute use during the last years. How-
ever, since reimbursement of additional bone substitute application
depends on localization of the treated bone defect, monetary reasons
for increasing use of bone graft substitutes cannot be assessed con-
clusively by this study.
The use of cancellous bone grafts for both autologous and allo-
genic bone transplantation remained on a high level over the com-
plete observation period. More than three quarters of all autologous
and allogenic bone-grafting procedures were performed using cancel-
lous bone for each year between 2008 through 2018. Defect size,
morphology and anatomical location are crucial parameters for selec-
tion of bone graft materials. While in general, small defects with corti-
cal support are amenable for cancellous bone grafting procedures,
larger and sometimes segmental defects are often treated by cortical
bone grafting, which promises additional biomechanical stability.
Depending on anatomic location favorable results have been reported
for segmental bone defects with a size between 2.5 and 6 cm.1,15 In
addition, newer procedures such as the Masquelet technique have
been developed over the last years, demonstrating consolidation of
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cancellous bone grafting in major defects up to 26 cm. An induced
membrane which supplies the bone defect zone with blood and
thus with osteoinductive growth factors is held responsible for
good results even in larger bone defects.16,17 The need for osteo-
inductive potential in bone defect healing has been realized early
in 1965 by Marshall R. Urist.18 Based on the present results
improved allograft materials, however, which contain additional
osteoinductive growth factors such as demineralized bone matrix,
seem to have entered the focus of clinical application only over the
last decade.19 From 2008 through 2018 the use of demineralized
bone matrix increased from 288 to 1,355 procedures which corre-
sponds to an increase of 370.5%.
The use of bone graft substitutes experienced the largest increase
over the observed 11-year period compared to autologous and allo-
genic bone grafting. Based on the data provided by Destatis, it was
possible to discriminate between ceramics, cements and other bioma-
terials. During the observed period ceramics were the largest group of
used bone graft substitutes. Bone cements were a little less often
used. For both biomaterial groups a large increase could be observed
over time (ceramics +127.7%, cements +91.9%). For other biomate-
rials, an even larger increase of 365.8% could be observed from 2008
through 2018. This might be due to development of metallic bone
augments such as trabecular tantalum based components or bioactive
glass, which emerged as bone substitute material for bone defect
reconstruction in the 1990s and experienced optimization of material
properties since then.20
When analyzing total numbers and trends in use of various bone
grafting materials by orthopedic surgeons in Germany, it has to be
mentioned, that biomaterial sciences is not covered and taught in
medical school. In contrast to pharmacology, which is a core course
in all medical school curricula, biomaterial sciences, which often deal
with materials and devices intended for permanent implantation as
well as the interaction of materials and living tissues, is not taught in
the context of medical school education or orthopedic residency. As a
result, a thorough understanding of the importance of material prop-
erties with regard to cell and tissue responses and ultimately clinical
outcomes is often not generated during medical and surgical training.
Improving this knowledge base may have major potential for a more
enlightened use of biomaterials in clinical practice. The present data
underline the need to overthink current medical education curricula
since a further increase in use of artificial bone grafts and other bio-
materials has to be expected.
Intriguingly, application of antibiotic-loaded biomaterials
increased considerable (+194%) between 2008 and 2018. Beside
absolute numbers the proportion of antibiotic-loaded bone graft
substitutes increased as well (2008: 25% vs. 2018: 32.8%). The rel-
evance of local application of antibiotics for prophylaxis of infec-
tion in open fractures as well as crucial treatment element in
bone infections has become increasingly evident in recent
years.8,21 This might be the reason for the observed trend of
increased use of bone substitutes with antibiotic supplement.
The well-known beneficial effect of antibiotic-loaded polymethyl
methacrylate (PMMA) in arthroplasty might be another reason.22,23
Additionally, commercially available and market approved antibiotic-
loaded ceramic composites and further improved treatment concepts
render a routinely clinical use.24
Even if the described trends of increasing use of artificial bone
graft substitutes is impressive, this trend cannot simply be projec-
ted to the coming years. Beside events such as the COVID-19
pandemic, new regulatory requirements, such as the introduction
of the medical device regulation (MDR), challenge biomaterial
manufacturers within the European Union. Especially smaller com-
panies might not be able to fulfill the demanded requirements
which include recertification of medical devices including bone
grafting materials every five years for every given application.
Companies consecutively might withdraw their bone graft substi-
tute products from the market. Besides, cost intensive invest-
ments in research and development are likely to be reduced due to
regulatory and financial requirements for a market launch of a new
bone graft substitute.25 Although those regulations possibly hin-
der market introduction of new promising bone graft substitutes,
improved demands on manufacturers to achieve patient safety are
likely to achieve trust in health care providers. In the 1970s,
1980s and 1990s numerous bone grafting materials were intro-
duced into the market based on equivalence to existing materials
without detailed data from preclinical large animal studies as well
as prospective clinical studies for the given application.26 Clinical
outcomes of various bone graft materials for various procedures
have not been sufficiently followed-up. New regulations leading
to well-documented safety and positive results in terms of bone
reconstruction achieved by bone graft substitutes, however, might
improve surgeons' confidence in the application of artificial bone
graft substitutes. Thusly, an increase in clinical application would
also be conceivable.
Our study has several limitations. The analyzed data provided by
the Federal Statistical Office covers all inpatient hospital cases. Thus, it
can be assumed that all usually complicated cases requiring inpatient
treatment for bony defect reconstruction were assessed. The large
sample of annual 86,294 (2008) to 106,953 procedures (2017) comes
along with possible coding errors which might lead to distortion of the
presented results. DRG coding specialists who are usually available in
all hospitals might minimize such a bias. Nevertheless, specialists in the
field of accounting might not overview the chemical compositions of
different bone substitutes and correct classification of the correct OPS
codes. For example, confusion of calcium phosphate cements with
PMMA-based cements cannot be excluded. Even if the presented trend
over the last 11 years provides an excellent overview for the stated
research questions, it is not possible to derive a projection for future
clinical use from the presented data. New insights in the field of bioma-
terials research, price development and product availability may influ-
ence future trends and each of them cannot be foreseen. Beside
economic factors, which are known to play a pivotal role for the health
care systems, remuneration in the DRG system is a decisive factor for
future treatment decisions for or against application of bone grafts or
bone substitutes in clinical practice. Those trends cannot be derived for
the future from the present data analysis.
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5 | CONCLUSION
Bone graft substitutes as well as allogenic bone graft procedures gain
more and more importance for bone defect reconstruction in clinical
practice. They are the key drivers for an increase in total numbers of
bone graft and bone substitute applications from 2008 through 2018.
Absolute and relative numbers of the gold standard autologous bone
graft decreased in recent years, despite being the preferred choice in
more than half of the cases for bone defect reconstruction. A further
increase in use of bone graft substitutes can be expected if
further improvements in materials are made, as it can be seen in the
local application of antibiotics.
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